For research use only. Not for human consumption. Not evaluated by the FDA.

Melanotan-2 is the newest melanocortin compound in this library, and it's important to place it correctly: it's the broader-acting and higher-risk cousin of Melanotan-1, and a relative of PT-141. If you read the earlier melanotan and PT-141 posts, this fills in the specific MT-2 picture. Like MT-2's whole family, the science is real, but this is another one where the "research use only" framing reflects genuine safety reality rather than a formality, it has documented serious risks. So this entry stays cautious, and the risk section is the important part. Here's the honest rundown.

What it actually is, and how it differs from its relatives

Melanotan-2 (MT-2) is a synthetic cyclic peptide, an analog of alpha-melanocyte-stimulating hormone (alpha-MSH), the same parent hormone behind Melanotan-1 and PT-141. It was developed in the 1980s at the University of Arizona, originally as a sunless tanning agent intended to reduce skin cancer risk (the idea: tan without UV damage), but during testing it was found to strongly affect sexual function and appetite too.

The key thing is how MT-2 relates to its family members, because they're often confused and their risk profiles differ significantly:

• Melanotan-1 (afamelanotide) is more MC1R-selective (mostly pigmentation). It's actually FDA-approved as Scenesse, a slow-release implant given by clinicians for a rare disease (erythropoietic protoporphyria). Relatively benign safety profile.
• PT-141 (bremelanotide) was refined out of MT-2 to isolate the sexual-desire effect. It's FDA-approved as Vyleesi for a specific condition.
• Melanotan-2 is the non-selective, broad-acting one, and it's not approved anywhere. It's the black-market "tanning + libido" compound.

So within this family, MT-2 is the outlier: the broadest-acting and the only one with no approved medical use. The shared chemistry links them, but their regulatory status, oversight, and safety are not the same, and it's a mistake to treat MT-2 as equivalent to its approved relatives.

How it works, and why "non-selective" is the crux

MT-2 binds melanocortin receptors, but the critical fact is that it's non-selective and extremely potent, up to ~1000 times more potent than natural alpha-MSH, and it hits multiple receptor types at once (MC1R, MC3R, MC4R, MC5R). That means it triggers several unrelated effects across different body systems simultaneously, which is the root of its messy and sometimes dangerous side-effect profile.

By receptor:

• MC1R (skin): stimulates melanin production → tanning (the intended effect). Cumulative, and accelerated by UV.
• MC4R (brain): suppresses appetite and triggers sexual arousal/erections.
• MC3R and MC5R: additional, less predictable effects on energy and other systems.

So unlike a targeted drug, MT-2 throws multiple switches at once. The tan is what people are after; the appetite suppression, the sexual effects, and the rest come along whether wanted or not. Notably, MT-2 is even broader-acting than MT-1 (which is more pigmentation-focused), which is exactly why MT-2 carries more wide-ranging risks.

What the evidence shows

The tanning effect is real, MT-2 is at least as effective as MT-1 at darkening skin, and early pilot studies confirmed the pigmentation and the erection-stimulating effects (one small study noted erectile response in most men treated). But MT-2's development as a drug was halted over safety concerns, it never completed proper large trials, and it has never been approved by any regulatory authority. So the "evidence" is mostly early pilot work plus a substantial and worrying case-report literature (see below). The bulk of what we know about MT-2 in real-world use comes from documented harms, not controlled efficacy studies.

The risks (this is the section that matters most)

MT-2 carries a documented, multi-system risk profile that's more concerning than most compounds in this library, and these come from real case reports in the medical literature:

Priapism. Because MT-2 activates the MC4R erection pathway non-selectively, prolonged, painful erections (priapism) are a documented risk, occurring 1-5 hours after use, associated with the characteristic yawning-and-stretching effect. Priapism is a genuine medical emergency that can cause permanent damage if untreated.

Moles and melanoma concern. MT-2 causes darkening and proliferation of moles, including atypical (dysplastic) ones, and there are individual case reports of melanoma and melanoma in situ in users. To be precise and fair: the causal link is genuinely unresolved, a 2013 systematic review found no conclusive evidence that MT-2 causes melanoma, and elevated melanoma rates in users may be partly explained by the fact that people using a tanning drug also seek more UV. But two concerns remain serious regardless: stimulating melanocyte activity in predisposed people is theoretically risky, and, importantly, widespread mole darkening makes it much harder to spot the real warning signs of melanoma. Even setting aside causation, that masking effect alone is a real problem.

Kidney and muscle damage. Documented case reports include rhabdomyolysis (dangerous muscle breakdown), acute kidney injury, and even renal infarction.

Cardiovascular effects. Elevated blood pressure and heart rate are reported.

Neurological. There's even a case report of posterior reversible encephalopathy syndrome (PRES), a serious brain condition, associated with MT-2 use.

Common side effects. Even the routine ones are notable: nausea, facial flushing, spontaneous yawning and stretching, fatigue, and decreased appetite.

Purity and contamination. Because it's illegal to sell for human use, products sold online and in gyms have no quality control, adding contamination, mislabeling, and inconsistent dosing on top of the compound's own risks.

One more genetic wrinkle: MC1R genotype affects the pigmentation response, so results are heterogeneous and unpredictable between individuals.

The regulatory reality

This is clear-cut. Melanotan-2 is not approved by the FDA or any major regulator, and its development was specifically halted over safety concerns. It's illegal to sell for human use in most countries, and it can legally be supplied only to licensed researchers for non-human experimental purposes. Regulators (and dermatology reviews, like the comprehensive 2017 Habbema review) explicitly distinguish MT-2's black-market status from its approved relatives and caution against treating them as equivalent. For MT-2 specifically, "for research use only, not for human consumption" reflects the actual legal and safety reality.

Status

Melanotan-2 is not approved anywhere; its development was halted over safety concerns. It's illegal to sell for human use in most countries and is genuinely a research chemical. This is distinct from its approved relatives afamelanotide (MT-1/Scenesse) and bremelanotide (PT-141/Vyleesi).

The honest bottom line

Melanotan-2 is one of the more cautionary entries in this library, and it's worth stating that plainly rather than softening it. Within the melanocortin family, it's the broad-acting, non-selective, unapproved outlier, more wide-ranging than the pigmentation-focused MT-1, and lacking the narrow approved use of PT-141. The tanning effect is real, but it comes bundled with appetite, sexual, and multi-system effects you can't opt out of, and its development was halted over safety concerns for good reason.

The documented risk profile, priapism, mole proliferation with an unresolved-but-serious melanoma concern (plus a real cancer-detection-masking problem), rhabdomyolysis, kidney injury, cardiovascular and even neurological events, all compounded by an unregulated black-market supply, places MT-2 in a genuinely riskier category than most peptides here. It's useful to understand, partly as the origin compound behind the much more refined PT-141, but understanding it honestly means recognizing it as a halted-development research chemical with real documented harms, not a casual cosmetic shortcut. The research-only framing on this one is the literal truth.

Sources / Further Reading

1. Habbema et al., Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues (comprehensive MT-II harm review), International Journal of Dermatology (2017) — https://pubmed.ncbi.nlm.nih.gov/?term=habbema+melanotan+melanocyte+stimulating+hormone+risks
2. Melanotan tanning injection: a rare cause of priapism (case report), NCBI PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC7930850/
3. Dorr et al., Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide (pilot Phase 1), Life Sciences (1996) — https://pubmed.ncbi.nlm.nih.gov/8637005/
4. Overview of benefits and risks of chronic melanocortin-1 receptor activation, NCBI PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC11664455/
5. Melanotan II overview (pharmacology, documented adverse effects) — https://dermnetnz.org/topics/melanotan-ii

This overview summarizes publicly available research for educational purposes. It is not medical advice and not a recommendation to use any compound. Melanotan-2 is not approved for human use, its development was halted over safety concerns, and it carries documented serious risks.